Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07493551 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Bioequivalence Study of PP3M in Patients With Schizophrenia

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To evaluate the bioequivalence of the test formulation paliperidone palmitate injection (3M) produced by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. and the reference formulation paliperidone palmitate injection (3M) (brand name: Invega Trinza) by Janssen Pharmaceutica N.V. under multiple-dose administration.
Trial Details
NCT Number NCT07493551
Lead Sponsor CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions
(from sponsor)		 Schizophrenia
Related terms Schizophrenia
Enrollment 260 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov